NASDAQ:VKTX Viking Therapeutics (VKTX) Stock Price, News & Analysis $38.71 +1.27 (+3.39%) Closing price 04:00 PM EasternExtended Trading$38.44 -0.27 (-0.71%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Viking Therapeutics Stock (NASDAQ:VKTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Viking Therapeutics alerts:Sign Up Key Stats Today's Range$37.10▼$38.8750-Day Range$27.75▼$39.5452-Week Range$22.96▼$43.15Volume2.12 million shsAverage Volume2.68 million shsMarket Capitalization$4.49 billionP/E RatioN/ADividend YieldN/APrice Target$93.60Consensus RatingModerate Buy Company Overview Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders. The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions. Viking conducts Phase 2 clinical trials for these candidates, evaluating safety, tolerability and efficacy across multiple patient populations. Viking Therapeutics maintains operations across the United States, engaging with clinical research sites to enroll patients in its ongoing studies. The company also collaborates with academic institutions and regulatory agencies to advance trial designs and biomarker strategies that support its drug development objectives. Under the leadership of President and Chief Executive Officer David A. Woodhouse, Viking has built a management team with extensive experience in endocrinology, metabolic disease and biopharmaceutical development. The company’s strategic focus remains on progressing its pipeline through clinical milestones and exploring opportunities to extend its proprietary technology platform into additional indications.AI Generated. May Contain Errors. Read More Viking Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreVKTX MarketRank™: Viking Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 389th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingViking Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 2 strong buy ratings, 8 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialViking Therapeutics has a consensus price target of $93.60, representing about 141.8% upside from its current price of $38.71.Amount of Analyst CoverageViking Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viking Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Viking Therapeutics are expected to grow in the coming year, from ($4.70) to ($4.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viking Therapeutics is -9.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viking Therapeutics is -9.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViking Therapeutics has a P/B Ratio of 6.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viking Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.21% of the float of Viking Therapeutics has been sold short.Short Interest Ratio / Days to CoverViking Therapeutics has a short interest ratio ("days to cover") of 11.64, which indicates bearish sentiment.Change versus previous monthShort interest in Viking Therapeutics has recently increased by 4.23%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViking Therapeutics does not currently pay a dividend.Dividend GrowthViking Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.56 News SentimentViking Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Viking Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 32 people have searched for VKTX on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows26 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 63% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Viking Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.30% of the stock of Viking Therapeutics is held by insiders.Percentage Held by Institutions76.03% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Viking Therapeutics' insider trading history. Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VKTX Stock News HeadlinesHow Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?July 5 at 1:05 AM | fool.comIs Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are SayingJuly 4 at 5:10 AM | fool.com4th of July Chaikin flash saleMarc Chaikin - the 60-year Wall Street veteran who called Nvidia before it surged 45,000% - is running his first-ever 4th of July flash sale through July 6th only. His Power Gauge Report membership comes with a free year of access to his Power Gauge Rating system, a 100% money-back guarantee, and a Hotlist of buy and sell ideas - including a little-known Nvidia partner he calls 'an upgrade to Tesla stock' in the autonomous vehicle race. His tools are used on Bloomberg and Reuters terminals worldwide and have helped investors grow assets by as much as 69,000%.July 6 at 1:00 AM | Chaikin Analytics (Ad)Here's Why Viking Therapeutics Stock Surged Higher in JuneJuly 3 at 2:09 PM | fool.comCantor Fitzgerald Remains a Buy on Viking Therapeutics (VKTX)July 3 at 8:42 AM | theglobeandmail.comViking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to KnowJuly 1, 2026 | finance.yahoo.comIs Viking Therapeutics Stock Going to $100?July 1, 2026 | fool.comIs It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?June 29, 2026 | finance.yahoo.comSee More Headlines VKTX Stock Analysis - Frequently Asked Questions How have VKTX shares performed this year? Viking Therapeutics' stock was trading at $35.18 at the beginning of the year. Since then, VKTX shares have increased by 10.0% and is now trading at $38.71. How were Viking Therapeutics' earnings last quarter? Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its quarterly earnings results on Thursday, April, 30th. The biotechnology company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.01) by $0.36. Read the conference call transcript. When did Viking Therapeutics IPO? Viking Therapeutics (VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager. How do I buy shares of Viking Therapeutics? Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Viking Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viking Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Invesco QQQ (QQQ), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD). Company Calendar Last Earnings4/30/2026Today7/06/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 VKTX's financial health is in the Green zone, according to TradeSmith. VKTX has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VKTX CIK1607678 Webwww.vikingtherapeutics.com Phone(858) 704-4660FaxN/AEmployees20Year Founded2012Price Target and Rating Average Price Target for Viking Therapeutics$93.60 High Price Target$125.00 Low Price Target$38.00 Potential Upside/Downside+141.8%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($4.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$359.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-71.31% Return on Assets-65.35% Debt Debt-to-Equity RatioN/A Current Ratio5.72 Quick Ratio5.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.65 per share Price / Book6.85Miscellaneous Outstanding Shares116,110,000Free Float109,952,000Market Cap$4.49 billion OptionableOptionable Beta0.66 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:VKTX) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our Partners4th of July Chaikin flash saleMarc Chaikin - the 60-year Wall Street veteran who called Nvidia before it surged 45,000% - is running his fir...Chaikin Analytics | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Tech forecaster George Gilder - who identified Amazon when it was still just an online bookstore and predicted...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredMove your money (NOT into the next AI IPO)While headlines focus on AI IPOs, the world's largest investors are moving capital into one asset at the faste...Stansberry Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored770% to 3,300%. It's happening again.When shale went mainstream, five stocks returned 770% to 3,300% - Continental, EOG, ONEOK. That same drilling ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VKTX Stock Alerts